Pelagos Pharmaceuticals

Pelagos is developing orally bioavailable small molecule drugs to target diseases of aging by modulating nuclear hormone receptors that regulate cellular metabolism. Its lead program targets estrogen-related receptor (ERR) to treat obesity while preserving muscle mass. A second program focuses on REV-ERB, a key regulator of the body’s circadian and metabolic processes, for the treatment of heart failure. By addressing previously undruggable pathways, Pelagos aims to create new treatment options for metabolic and cardiovascular diseases.